Drugs / SAR439459
SAR439459
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05231668 | Aug 2022 → Nov 2024 | osteogenesis imperfecta | Sanofi | Terminated | No outcome recorded |
| Phase 1 | NCT04729725 | Feb 2021 → Dec 2022 | high grade malignant neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT03192345 | Jun 2017 → Dec 2021 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04643002 | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR439459 | “anti-TGF-beta monoclonal antibody SAR-439459 (SAR439459)” NCT04729725 ↗ |
| Known as | GC-2008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298099 ↗ |
| Known as | SAR'459 | “SAR439459 (SAR'459), a "second-generation" human anti-transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors.” PMID 38898592 ↗ Jun 2024 |
| Action | Inhibit | “SAR439459, a pan-TGFβ neutralizing antibody, inhibits all active isoforms of human and murine TGFβ” PMID 33224628 ↗ Sep 2020 |
| Modality | Monoclonal antibody | “SAR439459 (SAR'459), a "second-generation" human anti-transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors.” PMID 38898592 ↗ Jun 2024 |
| Route | Intravenous | “Route of administration: intravenous infusion” NCT03192345 ↗ |